MAP2K7 and cancer: In Liu et al.’s study57, SIX5 expression had a statistically significant association with the response of cancer cells to the HER2 inhibitor Lapatinib (p-value 0.014) and the MEK inhibitor PD-0325901 (p-value 0.0184), both of which inhibit proliferation in cancer cells58, 59.